<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04579406</url>
  </required_header>
  <id_info>
    <org_study_id>ScondShanxiMU-1646</org_study_id>
    <nct_id>NCT04579406</nct_id>
  </id_info>
  <brief_title>Perioperative Adverse Cardiovascular Event in Type-2 Diabetic Patients</brief_title>
  <acronym>DMPACE</acronym>
  <official_title>Association of Changes in NPY, CGRP, SP and TRPV1 With Perioperative Adverse Cardiovascular Event in Type-2 Diabetic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Second Hospital of Shanxi Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Second Hospital of Shanxi Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study was designed to investigate the correlation between perioperative adverse&#xD;
      cardiovascular events and the degeneration of sensory nerves in patient diagnosed with type 2&#xD;
      diabetes mellitus, undergoing elective non-cardiac surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study was designed to investigate the correlation between perioperative adverse&#xD;
      cardiovascular events and the degeneration of sensory nerves in patient diagnosed with type 2&#xD;
      diabetes mellitus, undergoing elective non-cardiac surgery. Diabetes mellitus and peripheral&#xD;
      sensory nerve degeneration will be diagnosed via clinical evaluation. Serum levels of&#xD;
      constituent neuropeptides, including neuropeptide Y (NPY), calcitonin and substance P (SP)&#xD;
      and calcitonin gene related peptide (CGRP), and transient receptor potential vanilloid 1&#xD;
      (TRPV1), a molecular nociceptor in peripheral sensory nerves will be quantitatively&#xD;
      evaluated. The clinical and the biochemical consequence will be compared between the cohorts&#xD;
      of diabetic and non-diabetic patients. The differences and the correlations will be analyzed.&#xD;
      The results of the study may reveal whether or not the perioperative adverse cardiovascular&#xD;
      events in diabetic patients are correlated with degeneration of peripheral sensory nerves and&#xD;
      the alterations in the neuropeptides and TRPV1 are potentially applicable for evaluation of&#xD;
      the risk of cardiovascular events in perioperative period in diabetic patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 15, 2020</start_date>
  <completion_date type="Anticipated">October 14, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 14, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>adverse cardiovascular events</measure>
    <time_frame>Perioperative period</time_frame>
    <description>All the pre-, intra- and post-operative adverse cardiovascular events in the patients will be taken into account.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>NPY, CGRP, SP and TRPV1</measure>
    <time_frame>Perioperative period</time_frame>
    <description>The difference in the serum levels of NPY, CGRP, SP and TRPV1</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Type 2 Diabetes</condition>
  <condition>Neuropathy</condition>
  <arm_group>
    <arm_group_label>non-diabetic group</arm_group_label>
    <description>The non-diabetic patients undergoing non-cardiac surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Diabetic group</arm_group_label>
    <description>The diabetic patients without peripheral neuropathy undergoing non-cardiac surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Diabetic neuropathic group</arm_group_label>
    <description>The diabetic patients with peripheral neuropathy undergoing non-cardiac surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>non-cardiac surgery</intervention_name>
    <description>All the patients are undergoing non-cardiac surgery.</description>
    <arm_group_label>Diabetic group</arm_group_label>
    <arm_group_label>Diabetic neuropathic group</arm_group_label>
    <arm_group_label>non-diabetic group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Type 2 diabetic patients with and without peripheral sensory neuropathy&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The main discharge diagnosis is T2DM；&#xD;
&#xD;
          -  Age &gt; 18 years old;&#xD;
&#xD;
          -  No acute complications of diabetes&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  T1DM patients;&#xD;
&#xD;
          -  EGFR &lt; 60 ml/min/1.73 m or proteinuria (or both);&#xD;
&#xD;
          -  Patients with history of acute cardiovascular events;&#xD;
&#xD;
          -  Familial hypercholesterolemia or other hereditary lipid metabolism diseases;&#xD;
&#xD;
          -  anti-HIV patients;&#xD;
&#xD;
          -  Patients with serious mental health problems;&#xD;
&#xD;
          -  Patients receiving drugs that can lead to dyslipidemia, such as antipsychotics,&#xD;
             corticosteroids, or immunosuppressants;&#xD;
&#xD;
          -  Patients with systemic inflammatory diseases, such as systemic lupus erythematosus;&#xD;
&#xD;
          -  Patient are quitting smoking and severe obesity (BMI&gt;40)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zheng Guo, M.B., Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Second Hospital of Shanxi Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zheng Guo, M.B., Ph.D.</last_name>
    <phone>+863513365790</phone>
    <email>guozheng713@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Zheng Guo</name>
      <address>
        <city>Taiyuan</city>
        <state>Shanxi</state>
        <zip>030001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zheng Guo, MB，PhD</last_name>
      <phone>+863513365790</phone>
      <email>guozheng713@yahoo.com</email>
    </contact>
    <contact_backup>
      <last_name>Weijun Liang, MSc</last_name>
      <phone>+863513365790</phone>
      <email>weijun_liang@126.com</email>
    </contact_backup>
    <investigator>
      <last_name>Zheng Guo, MB, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>October 1, 2020</study_first_submitted>
  <study_first_submitted_qc>October 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 8, 2020</study_first_posted>
  <last_update_submitted>March 15, 2021</last_update_submitted>
  <last_update_submitted_qc>March 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Second Hospital of Shanxi Medical University</investigator_affiliation>
    <investigator_full_name>Zheng Guo</investigator_full_name>
    <investigator_title>Professor and chairman of the Department of Anesthesiology</investigator_title>
  </responsible_party>
  <keyword>Diabetes mellitus</keyword>
  <keyword>adverse cardiovascular events</keyword>
  <keyword>nerve degeneration</keyword>
  <keyword>peripheral sensory nerves</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Yes, if possible.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

